A specific lawsuit claiming Foundation Medicine licensed genomic profiling data to insurers without disclosure has not been publicly verified or documented in legal databases. However, Foundation Medicine has faced significant litigation regarding transparency and proper disclosure in its dealings with insurance companies, including a major stock fraud case that centered on misleading statements about Medicare coverage for genomic tests.
Table of Contents
- What Does Foundation Medicine Actually Do With Genomic Data?
- The Stock Fraud Lawsuit and Misleading Medicare Claims
- Unresolved Insurance Reimbursement and Payment Issues
- Patent Disputes and Competitive False Advertising
- What Patient Consent Forms Actually Say
- Implications for Patients Considering Genomic Profiling
- What’s Changed and What Hasn’t
What Does Foundation Medicine Actually Do With Genomic Data?
Foundation Medicine is a molecular diagnostics company that performs comprehensive genomic profiling tests to identify cancer mutations and inform treatment decisions. When patients have these tests performed, the company does collect and process patient data, and its consent forms authorize sharing information with “third-party payers” (insurance companies) for reimbursement purposes.
However, the authorization is generally disclosed in consent documentation—though as of 2015, transparency regarding reimbursement processes and data handling has been contested in litigation. Foundation Medicine’s business model depends significantly on billing insurers for genomic profiling services, which creates potential conflicts between patient privacy and the company’s need to access insurance coverage information.
The Stock Fraud Lawsuit and Misleading Medicare Claims
In 2014-2015, the law firm Robbins Geller Rudman & Dowd filed a class action lawsuit against Foundation Medicine on behalf of stockholders, alleging that the company made false and misleading statements about Medicare coverage and reimbursement likelihood for its genomic tests. The complaint centered on Foundation Medicine’s public representations to investors about the certainty of Medicare payments, when in reality coverage remained uncertain and reimbursement claims faced systematic delays.
This lawsuit demonstrates that Foundation Medicine’s transparency issues weren’t limited to patient data practices—the company also misrepresented its financial prospects and insurance relationships to investors. The stock fraud case underscores a broader pattern of incomplete disclosure regarding how Foundation Medicine actually interacts with insurance systems.
Unresolved Insurance Reimbursement and Payment Issues
As of September 2015, Foundation Medicine reported significant problems with insurance payment for genomic tests. The company had billed commercial insurers for over 17,000 tests and reported results to more than 15,000 Medicare patients—but a substantial portion of those tests remained unpaid due to insurers’ lack of formal coverage decisions.
This meant patients and healthcare providers were left in limbo regarding whether tests would actually be covered, and Foundation Medicine faced uncertainty about revenue. The reimbursement gaps raise questions about what disclosure was made to patients: Did they know whether their insurance would actually cover the test before it was performed? Were they informed about Foundation Medicine’s track record with delayed or denied reimbursement? These gaps in transparency about real-world reimbursement outcomes affect patient decision-making and financial liability.
Patent Disputes and Competitive False Advertising
Foundation Medicine has also been involved in patent and advertising disputes with competitors like Guardant Health, settling claims over false advertising regarding the capabilities and accuracy of their respective genomic profiling assays (FoundationACT vs. Guardant360).
These disputes involved allegations that both companies made exaggerated or misleading claims about their tests’ ability to detect mutations and guide treatment. This litigation history indicates that Foundation Medicine’s transparency problems extend to marketing claims about test accuracy and clinical utility—not just data handling. When a company faces multiple lawsuits over misrepresentation, it raises broader questions about whether all information provided to patients (about what the test can detect, how data will be used, and insurance coverage) has been consistently accurate.
What Patient Consent Forms Actually Say
Foundation Medicine’s patient consent and test requisition forms do include authorizations for sharing genomic data with third-party payers for purposes of insurance billing and coverage determination. However, the specificity and clarity of these disclosures, and whether patients truly understand the scope of data sharing involved, remains a legitimate point of concern—especially given the company’s documented litigation over incomplete or misleading disclosures in other contexts.
A patient signing a consent form may not realize that “sharing data with insurers” can involve transmitting detailed genetic information, test results, and clinical context to insurance company servers. There’s a difference between legal authorization and meaningful informed consent; Foundation Medicine’s litigation history suggests the company has sometimes blurred that line.
Implications for Patients Considering Genomic Profiling
Anyone considering Foundation Medicine’s genomic profiling test should understand several practical realities: First, there is no guarantee that insurance will cover the test, even after it’s performed—as of 2015, thousands of tests went unpaid. Second, your genomic data will be shared with insurance companies as part of the billing process, which Foundation Medicine discloses but not always with sufficient emphasis on what that means for privacy.
Third, Foundation Medicine has a history of legal disputes over false or incomplete disclosure, which suggests you should carefully review any consent forms and ask direct questions about coverage likelihood and data handling. Consider getting written confirmation from your insurance company about coverage before undergoing the test, rather than relying on Foundation Medicine’s or your provider’s assurances.
What’s Changed and What Hasn’t
Since 2015, Foundation Medicine was acquired by Roche Holding AG, which may have improved governance and transparency standards. However, the underlying business model—charging insurers for genomic tests and sharing patient data with payers—remains unchanged.
The company continues to operate in a complex regulatory environment where pressure to bill insurers aggressively can conflict with full transparency to patients. Genomic medicine is evolving rapidly, and reimbursement coverage has improved in some areas; however, patients should remain skeptical of any company’s claims about guaranteed insurance coverage or seamless data handling processes.